Cargando…

Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic

This study provides the longest follow-up yet for comprehensive behavioral (ComB) treatment of trichotillomania (TTM) (M = 24.59 months after pre-treatment and 15.92 months after the last follow-up point in a recent clinical trial (Carlson et al., 2021), which had shown ComB to be significantly more...

Descripción completa

Detalles Bibliográficos
Autores principales: Flannery, Meghan K., Coyne, Allison F., Carlson, Emily J., Haaga, David.A.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683380/
https://www.ncbi.nlm.nih.gov/pubmed/34956828
http://dx.doi.org/10.1016/j.jocrd.2021.100706
_version_ 1784617405199155200
author Flannery, Meghan K.
Coyne, Allison F.
Carlson, Emily J.
Haaga, David.A.F.
author_facet Flannery, Meghan K.
Coyne, Allison F.
Carlson, Emily J.
Haaga, David.A.F.
author_sort Flannery, Meghan K.
collection PubMed
description This study provides the longest follow-up yet for comprehensive behavioral (ComB) treatment of trichotillomania (TTM) (M = 24.59 months after pre-treatment and 15.92 months after the last follow-up point in a recent clinical trial (Carlson et al., 2021), which had shown ComB to be significantly more efficacious than minimal attention at post-treatment). This study also examined changes in TTM severity from before to during the COVID-19 pandemic. Participants (N = 23) completed a survey assessing current TTM symptoms, the impact of the pandemic on their coping with TTM, and their experience with ComB treatment. Self-reported symptom severity at this follow-up evaluation fell between the scores obtained at the clinical trial’s pre-treatment assessment and at its last follow-up before the pandemic and did not significantly differ from either time point. Most participants (73%) reported some change in their TTM management since onset of the pandemic, with changes to their environment/routine (61%) and in anxiety (32%) being the most common. Pandemic-related changes were associated with variable outcomes, improving symptoms and management for some while worsening them for others. Use of strategies from ComB had declined since the most recent follow-up, but more than half (55%) of participants reported that strategies from ComB remained useful.
format Online
Article
Text
id pubmed-8683380
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-86833802021-12-20 Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic Flannery, Meghan K. Coyne, Allison F. Carlson, Emily J. Haaga, David.A.F. J Obsessive Compuls Relat Disord Article This study provides the longest follow-up yet for comprehensive behavioral (ComB) treatment of trichotillomania (TTM) (M = 24.59 months after pre-treatment and 15.92 months after the last follow-up point in a recent clinical trial (Carlson et al., 2021), which had shown ComB to be significantly more efficacious than minimal attention at post-treatment). This study also examined changes in TTM severity from before to during the COVID-19 pandemic. Participants (N = 23) completed a survey assessing current TTM symptoms, the impact of the pandemic on their coping with TTM, and their experience with ComB treatment. Self-reported symptom severity at this follow-up evaluation fell between the scores obtained at the clinical trial’s pre-treatment assessment and at its last follow-up before the pandemic and did not significantly differ from either time point. Most participants (73%) reported some change in their TTM management since onset of the pandemic, with changes to their environment/routine (61%) and in anxiety (32%) being the most common. Pandemic-related changes were associated with variable outcomes, improving symptoms and management for some while worsening them for others. Use of strategies from ComB had declined since the most recent follow-up, but more than half (55%) of participants reported that strategies from ComB remained useful. Elsevier Inc. 2022-01 2021-12-18 /pmc/articles/PMC8683380/ /pubmed/34956828 http://dx.doi.org/10.1016/j.jocrd.2021.100706 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Flannery, Meghan K.
Coyne, Allison F.
Carlson, Emily J.
Haaga, David.A.F.
Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic
title Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic
title_full Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic
title_fullStr Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic
title_full_unstemmed Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic
title_short Extended follow-up of a comprehensive behavioral (ComB) treatment sample during the COVID-19 pandemic
title_sort extended follow-up of a comprehensive behavioral (comb) treatment sample during the covid-19 pandemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683380/
https://www.ncbi.nlm.nih.gov/pubmed/34956828
http://dx.doi.org/10.1016/j.jocrd.2021.100706
work_keys_str_mv AT flannerymeghank extendedfollowupofacomprehensivebehavioralcombtreatmentsampleduringthecovid19pandemic
AT coyneallisonf extendedfollowupofacomprehensivebehavioralcombtreatmentsampleduringthecovid19pandemic
AT carlsonemilyj extendedfollowupofacomprehensivebehavioralcombtreatmentsampleduringthecovid19pandemic
AT haagadavidaf extendedfollowupofacomprehensivebehavioralcombtreatmentsampleduringthecovid19pandemic